Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
September 11, 2020 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
August 25, 2020 07:50 ET
|
Ovid Therapeutics Inc.
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare...
Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome
August 25, 2020 07:00 ET
|
Ovid Therapeutics Inc.
Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo (p=0.0007) in the combined Dravet syndrome and Lennox-Gastaut syndrome...
Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 10, 2020 08:00 ET
|
Ovid Therapeutics Inc.
Announces completion of enrollment in the pivotal Phase 3 NEPTUNE trial with OV101 in Angelman syndrome; topline results expected in Q4 2020Multiple data readouts for soticlestat expected in Q3 2020,...
Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020
August 05, 2020 09:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome
July 23, 2020 07:00 ET
|
Ovid Therapeutics Inc.
Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing...
Ovid Therapeutics y Angelini Pharma firman un acuerdo exclusivo de licencia para desarrollar, fabricar y comercializar OV101 para el tratamiento del síndrome de Angelman en Europa
July 14, 2020 18:01 ET
|
Ovid Therapeutics Inc.
Angelini Pharma obtiene derechos exclusivos de desarrollo, fabricación y comercialización de OV101 (gaboxadol) para el tratamiento potencial del síndrome de Angelman en la Unión Europea y otros países...
Ovid Therapeutics dan Angelini Pharma Menandatangani Perjanjian Lesen Eksklusif untuk Membangunkan, Membuat dan Memperdagangkan OV101 bagi Rawatan Sindrom Angelman di Eropah
July 14, 2020 18:01 ET
|
Ovid Therapeutics Inc.
Angelini Pharma mendapat hak pembangunan, pembuatan dan pemerdagangan yang eksklusif terhadap OV101 (gaboxadol) sebagai rawatan berpotensi untuk sindrom Angelman di Kesatuan Eropah dan negara lain di...
Ovid Therapeutics und Angelini Pharma schließen exklusive Lizenzvereinbarung zur Entwicklung, Herstellung und Vermarktung von OV101 zur Behandlung des Angelman-Syndroms in Europa ab
July 14, 2020 18:01 ET
|
Ovid Therapeutics Inc.
Angelini Pharma erhält Exklusivrechte für die Entwicklung, Herstellung und Vermarktung von OV101 (Gaboxadol) zur potenziellen Behandlung des Angelman-Syndroms in der Europäischen Union und anderen...
Ovid Therapeutics和Angelini Pharma签订开发、生产和商业化独家许可协议以利用OV101在欧洲治疗天使综合征
July 14, 2020 18:01 ET
|
Ovid Therapeutics Inc.
Angelini Pharma获得OV101（gaboxadol）开发、生产和商业化独家权利，用于欧盟、欧洲经济区其他国家以及瑞士、土耳其、英国和俄罗斯天使综合征患者的潜在治疗 Ovid Therapeutics将获得2000万美元前期付款并将在实现开发、制造和销售里程碑后再获得高达2.125亿美元的付款；此外如成功实现商业化还将获得净销售额两位数百分比的特许权收入 Angelini...